Navigation Links
AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
Date:6/12/2008

able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with seven products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Synbiotics Corporation Announces Human Submission for FluDetect(R)
3. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
4. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
5. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
6. Indevus Announces Submission of New Drug Application
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
10. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
11. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 Manchester Pharmaceuticals, Inc.(TM) announced today ... On October 22, 2009, the US Food ... therapy for patients suffering from gallstones in whom ... disease or advanced age. ,, Chenodal prescriptions have ... Centric Health Resources ("Centric"), a specialty pharmacy company. ...
(Date:12/14/2009)... Dec. 14 Travelers of Interstate 70 west ... become a bit more colorful when 10 multicolored art ... is named going home , will eventually include ... a graduate student at Herron School of Art and ... Public Life. ,, Eli Lilly and Company (NYSE: ...
(Date:12/14/2009)... 14 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... of directors with the addition of Lt. Gen. Ronald ... chairman of Martin, Blanck & Associates, a federal health ... his addition, the company board now has nine members. ... as a medical officer and battalion surgeon in Vietnam. ...
Breaking Medicine Technology:Manchester Announces Availability of Chenodal(TM) 2Public Art to Complete Transformation of Key Gateway into Indianapolis 2Public Art to Complete Transformation of Key Gateway into Indianapolis 3Public Art to Complete Transformation of Key Gateway into Indianapolis 4Oxygen Biotherapeutics, Inc. Expands Board of Directors 2Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 1Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 2Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 3Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 4Cantel Medical Corp to Hold Conference Call to Discuss Results for its First Quarter Ended October 31 2009 6687 1Cantel Medical Corp to Hold Conference Call to Discuss Results for its First Quarter Ended October 31 2009 6687 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 6683 1AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 6683 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 6683 3
... FRANCISCO, Calif., Nov. 6 Portola,Pharmaceuticals, a ... advances in cardiovascular and inflammatory,diseases, and cancer, ... the,company,s novel oral Factor Xa inhibitor and ... presented at the American Heart Association,(AHA) Scientific ...
... Bavarian,Nordic has completed a clinical safety report from a ... that confirms the excellent,safety profile of IMVAMUNE(R). Within the ... be submitted to the FDA and this will trigger ... The clinical safety,report constitutes a major part of the ...
Other Medicine Technology:Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008 2Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R) 2
(Date:12/15/2009)... DALLAS Dec. 15, 2009 UT Southwestern ... account to date of the unique observable characteristics ... aging syndrome. , The findings, reported online and ... of Clinical Endocrinology and Metabolism, suggest that ... be lumped together with those diagnosed with two ...
(Date:12/14/2009)... ANN ARBOR, Mich., Dec. 14 ... and the Commonwealth of Kentucky are among the ... solution this fall to help their employees make ... Enrollment solution gives employees a personalized summary of ... cost of that care. With this personalized information, ...
(Date:12/14/2009)... -- Aflac Incorporated announced today that it has ... notes with a coupon of 6.9%. The notes ... to yield 6.984%. The company anticipates using the ... general corporate purposes. ,, Commenting on the pricing ... Chief Financial Officer Kriss Cloninger III commented: "This ...
(Date:12/14/2009)... gardening replaced tube watching , , MONDAY, Dec. 14 (HealthDay ... hours of television a week until he enrolled in ... time in half. , During his enforced period of ... not necessarily through strenuous exercise, although he did find ... time was spent reading and working on the computer, ...
(Date:12/14/2009)... Statement of Steve Pasierb, President ,, NEW ... of Michigan,s Monitoring the Future study (MTF) -- the ... 8th, 10th and 12th graders -- underscores that teens, ... continues to be a cause for concern, with an ... from friends and relatives. ,, Teen ...
Breaking Medicine News(10 mins):Health News:Researchers ID traits of people with rare accelerated aging syndrome 2Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4Health News:Cutting TV Time Burns More Calories 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3
... of ban on their export of seafood to Canada as ... the banned chemical Malachite green in the fish tissues.// ... follow strict stringent rules and should test all batches of ... Malachite green and its byproducts. Consumer Association of Canada feels ...
... a deadly potion was brought home in a very uncomfortable ... of the greatest footballers' died in London yesterday. // ... own liver failed in the aftermath of his boozing exploits. ... world over, mostly male, suffer from alcohol-related liver disease each ...
... Insulin like-Growth Factor (IGF-1) is required for both ... secretion of IGF is mediated by the pituitary ... and is associated with metabolic abnormalities including insulin ... drugs helps in production of IGF-1 in children’s ...
... view, of the ever-increasing threat about bird flu worldwide, there ... manufacture the drug.// Ranbaxy Laboratories has become the first Indian ... drug, Tamiflu. The drug is believed to get shipped to ... Roche would be invalid. ,We have sent small ...
... prices and breakdown of electricity supplies, upto 90,000 senior ... have warned.//,As the Meteorological Office has issued its second ... gas - essential to warm homes - while some ... winter. ,Charity organisations caring for the elderly warned ...
... ideal sleeping position for toddlers with a new study ... when they sleep on their backs rather than on ... likely to be experienced by children who have sleep ... ,The study observed nearly 60 ...
Other Medicine News:Health News:Harsh British Winter Could Kill Upto 90,000 Pensioners 2
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
Medicine Products: